Products
Clesrovimab Biosimilar Monoclonal Antibody (RSV F Protein) for Research
Cat No.: GMP-Bios-INN-1139
Anti-RSV gpF therapeutic antibody (Pre-made Clesrovimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Clesrovimab (development code MK-1654) is a monoclonal antibody targeting human respiratory virus (RSV) fusion glycoprotein F site IV. It is developed by Merck Sharp & Dohme for respiratory syncytial virus infections. It is in the preregistration stage.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1139-1mg | 1mg | 3090 |
| GMP-Bios-INN-1139-10mg | 10mg | |
| GMP-Bios-INN-1139-100mg | 100mg | |
| GMP-Bios-INN-1139-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Clesrovimab biosimilar, Whole mAb: Anti-RSV gpF therapeutic antibody |
| INN Name | Clesrovimab |
| Target | RSV gpF |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | 6ous:MN:OP:QR:ST:UV:WX/9mml:MN/9mmv:MN |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Merck Sharp & Dohme |
| Conditions Approved | na |
| Conditions Active | Respiratory syncytial virus infections |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
